[HTML][HTML] Tim-3 finds its place in the cancer immunotherapy landscape
N Acharya, C Sabatos-Peyton… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
The blockade of immune checkpoint receptors has made great strides in the treatment of
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …
TIM3 comes of age as an inhibitory receptor
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …
[PDF][PDF] High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is characterized by molecular heterogeneity with
diverse immune cell infiltration patterns, which has been linked to therapy sensitivity and …
diverse immune cell infiltration patterns, which has been linked to therapy sensitivity and …
A spatially resolved timeline of the human maternal–fetal interface
S Greenbaum, I Averbukh, E Soon, G Rizzuto… - Nature, 2023 - nature.com
Beginning in the first trimester, fetally derived extravillous trophoblasts (EVTs) invade the
uterus and remodel its spiral arteries, transforming them into large, dilated blood vessels …
uterus and remodel its spiral arteries, transforming them into large, dilated blood vessels …
TIM-3, a promising target for cancer immunotherapy
Y He, J Cao, C Zhao, X Li, C Zhou… - OncoTargets and …, 2018 - Taylor & Francis
Patients with malignant tumor treated with immunotherapy have received significant clinical
benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T …
benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T …
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy
Immune checkpoint blockade has shown unprecedented and durable clinical response in a
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …
wide range of cancers. T cell immunoglobulin and mucin domain 3 (TIM3) is an inhibitory …
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
H Wang, G Kaur, AI Sankin, F Chen, F Guan… - Journal of hematology & …, 2019 - Springer
Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …
Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression
MR Girotti, M Salatino, T Dalotto-Moreno… - Journal of Experimental …, 2019 - rupress.org
Hanahan and Weinberg have proposed 10 organizing principles that enable growth and
metastatic dissemination of cancer cells. These distinctive and complementary capabilities …
metastatic dissemination of cancer cells. These distinctive and complementary capabilities …
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
A Valeri, A García-Ortiz, E Castellano… - Frontiers in …, 2022 - frontiersin.org
Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …